Product Pipeline

"Resverlogix has made remarkable progress in developing molecules to enhance the transcription of ApoA-I, and we currently have our lead molecule RVX-208 in clinical development.
Based on a strong discovery platform, we continue to look for opportunities to expand and broaden our pipeline and move new molecules into development."
 

Dr. Gregory S. Wagner, Senior VP Research & Development
Due to the nature of the drug development process, Resverlogix’s product pipeline will change over time as programs move through this process. Please refer to Media Press Releases for any updates.